ME

MegaPro Biomedical Co. Ltd.

Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.

TPEX

Overview

Corporate Details

ISIN(s):
TW0006827009
LEI:
Country:
Malaysia
Address:
N/A
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

MegaPro Biomedical Co., Ltd. is a clinical-stage biotechnology company specializing in the development of nanomedicines. Leveraging its core technology platforms centered on nanoparticles and nano-micelles, the company engineers novel drug dosage forms and delivery systems. Its development pipeline focuses on niche indications, including oncology, hematology, and diagnostics. Key product candidates include MPB-1734, a new formulation anticancer drug; MPB-1514, a nano-iron injection for treating iron deficiency anemia; and MPB-1523, a magnetic resonance imaging (MRI) contrast agent for liver cancer detection. The company operates primarily as a research and drug application development entity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-30 04:05
Legal Proceedings Report
MegaPro s MPB-1734 Expected to Seek Prostate Cancer NDA via 505(b)(2) Pathway S…
English 7.1 KB

Automate Your Workflow. Get a real-time feed of all MegaPro Biomedical Co. Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MegaPro Biomedical Co. Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MegaPro Biomedical Co. Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.